ライフサイエンスコーパス: endothelin receptor

1 models of CHF by nonselectively antagonizing endothelin receptors.

2 y infusion of BQ123 (an antagonist of type A endothelin receptors, 1 micromol/min).

3 these sites in branchial arch extracts from endothelin receptor A (EdnrA) mutant and wild-type mouse

4 y by Jagged-Notch signaling and ventrally by endothelin receptor A (EDNRA) signaling.

5 The mRNA levels of prepro-ET-1, endothelin receptor A (ET(A)), and endothelin receptor B

6 Endothelin receptor A (ETA), a G protein-coupled recepto

7 In contrast, the endothelin receptor A (ETRA) antagonist BQ123 does not h

8 actility-related genes such as endothelin-1, endothelin receptor A and B, adrenomedullin, adrenomedul

9 s controlled by treatment with the selective endothelin receptor A antagonist BQ-123 in a dose-depend

10 Endothelin receptor A blockade in vitro did not improve

11 angiogenesis by Edn2 requires expression of Endothelin receptor A but not Endothelin receptor B in t

12 Conditional loss of endothelin receptor A in granulosa cells also decreased

13 inic acetylcholine receptor, heme oxygenase, endothelin receptor A, haptoglobin, tyrosine aminotransf

14 iomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).

15 ncreased cell surface expression of CCR7 via endothelin receptor A.

16 The finding of associations between endothelin receptors A and B and distinct clinical and i

17 stituted pyrrolidine-3-carboxylic acid based endothelin receptor-A antagonist.

18 The selective endothelin receptor-A antagonists sitaxsentan and ambris

19 e discovery of amidothiophenesulfonamides as endothelin receptor-A antagonists with high potency and

20 The consequences of endothelin receptor activation were examined in atrial t

21 c receptors, alpha-adrenergic receptors, and endothelin receptors (among others) have been associated

22 Pretreatment with endothelin receptor and selectin inhibitors blocked the

23 q/11) formed immunocomplexes with the type-A endothelin receptor and the 110alpha subunit of PI 3-kin

24 d podocyte loss through direct activation of endothelin receptors and NF-kappaB and beta-catenin path

25 ps Y-27632-treatment increased expression of endothelin receptors and of parathyroid hormone-like hor

26 ins, suggesting a functional linkage between endothelin receptors and the Gardos channel.

27 on of IL-6, transforming growth factor beta, endothelin receptor, and alpha-smooth muscle actin by no

28 henesulfonamides with potent ET(A)-selective endothelin receptor antagonism and the subsequent identi

29 Endothelin receptor antagonism has emerged as an importa

30 fibroblasts, consistent with the notion that endothelin receptor antagonism may be beneficial in cont

31 designed to test the hypothesis that chronic endothelin receptor antagonism preserves coronary endoth

32 Chronic endothelin receptor antagonism preserves coronary endoth

33 The current study demonstrates that chronic endothelin receptor antagonism prevents the increase in

34 Chronic endothelin receptor antagonism significantly increased c

35 Endothelin-receptor antagonism with oral bosentan is an

36 Administration of an endothelin receptor antagonist (ETRA, SB 209670) to dogs

37 Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel

38 ciated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy.

39 Treatment with the endothelin receptor antagonist bosentan may be effective

40 The endothelin receptor antagonist BQ-485 (ET(A) selective)

41 The endothelin receptor antagonist is among the most effecti

42 us epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type

43 These effects were prevented by the endothelin receptor antagonist PD145065 (10 microM) and

44 Administration of a nonselective endothelin receptor antagonist provided essentially equi

45 udy examined the effects of the nonselective endothelin receptor antagonist SB-209,670, and the less

46 The endothelin receptor antagonist tezosentan did not improv

47 Tezosentan is a dual endothelin receptor antagonist that has been shown to im

48 Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemody

49 Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the

50 mendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong reco

51 We used a specific endothelin receptor antagonist to determine whether ET-1

52 a 12-month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc-rel

53 BMS182874, an endothelin receptor antagonist, blocks the effects of ex

54 We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the

55 Atrasentan, an endothelin receptor antagonist, has shown activity in pr

56 he efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized

57 nd safety of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with moderat

58 sess the hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with PHT, in

59 n of the endothelin system with bosentan, an endothelin receptor antagonist, was strongly protective

60 tment naive or on background therapy with an endothelin receptor antagonist, were eligible.

61 the current practice of adding bosentan, an endothelin receptor antagonist.

62 liminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercis

63 The endothelin-receptor antagonist bosentan is beneficial in

64 the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can be taken orally,

65 essed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poin

66 ral phosphodiesterase-5 inhibitor or an oral endothelin-receptor antagonist.

67 Endothelin receptor antagonists (ERA) and phosphodiester

68 Preclinical studies have demonstrated that endothelin receptor antagonists (ERAs) can reduce or pre

69 Oral endothelin receptor antagonists (ERAs) have been shown t

70 s of disease-targeted therapy (predominantly endothelin receptor antagonists [47.3%] or phosphodieste

71 -3-methyl-glutaryl-CoA reductase inhibitors, endothelin receptor antagonists and phosphodiesterase ty

72 Conversely, endothelin receptor antagonists and/or KIT blocking anti

73 hese findings raise the possibility of using endothelin receptor antagonists as neuroprotective agent

74 These data do not support the use of endothelin receptor antagonists as therapy for ILD secon

75 Endothelin receptor antagonists have emerged as a novel

76 roenvironment and further support the use of endothelin receptor antagonists in the treatment of inva

77 changes of HPS and the effects of selective endothelin receptor antagonists in vivo were assessed af

78 Additionally, infusion of endothelin receptor antagonists into the bursa of wild-t

79 Moreover, endothelin receptor antagonists may have a therapeutic r

80 The vasodilator properties of endothelin receptor antagonists may prove valuable thera

81 y hypoxia but attenuated by either selective endothelin receptor antagonists or oligonucleotides targ

82 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both.

83 g at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.

84 he treatment of PAH: prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase t

85 In cells treated with endothelin receptor antagonists, hydrogen peroxide scave

86 erent classes of drugs are now available-ie, endothelin receptor antagonists, phosphodiesterase-5 inh

87 se biological effects that are unaffected by endothelin receptor antagonists.

88 bitors, niacin, inhaled carbon monoxide, and endothelin receptor antagonists.

89 Endothelin-receptor antagonists are in clinical use to t

90 hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) pros

91 the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.

92 Although endothelin-receptor antagonists reduce albuminuria in di

93 pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study en

94 Endothelin receptors are also expressed on the human ecc

95 sults indicate that at least two subtypes of endothelin receptors are present on canine bronchial smo

96 Endothelin receptors are widely distributed throughout a

97 The number of endothelin receptors associated with bronchial contracti

98 Pharmacological antagonists of endothelin receptors attenuate cardiac hypertrophy, have

99 have identified alterations in expression of endothelin receptor B (EDNRB) as a potential factor that

100 The 5' region for the endothelin receptor B (EDNRB) gene is a complex CpG isla

101 damage also leads to a >10-fold increase in endothelin receptor B (Ednrb) in Muller cells 24 h after

102 Endothelin receptor B (EDNRB) is a G-protein-coupled rec

103 Loss of Endothelin-3/Endothelin receptor B (EDNRB) signaling leads to agangli

104 ts in Hirschsprung disease, we observed that Endothelin receptor B (Ednrb)-deficient gut NCSCs engraf

105 known genes, 67-kDa laminin receptor (67LR), endothelin receptor B (ENDRB), Na+/K+-ATPase, Ku antigen

106 pro-ET-1, endothelin receptor A (ET(A)), and endothelin receptor B (ET(B)) were measured by quantitat

107 Activation of the endothelin receptor B (ETRB) in cultured melanocyte prec

108 We observed that endothelin receptor B [ET-B (gene name EDNRB)], the rece

109 The endothelin receptor B gene (Ednrb) encodes a G-protein-c

110 The endothelin receptor B gene, a possible tumor suppressor

111 expression of Endothelin receptor A but not Endothelin receptor B in the neural retina.

112 ing chromosomal deficiencies surrounding the endothelin receptor B locus collected during the Oak Rid

113 eported modifier of hypopigmentation for the endothelin receptor B mouse model of WS4.

114 Mutations in the genes encoding endothelin receptor-B (Ednrb) and its ligand endothelin-

115 in ganglion cell number, while inhibition of endothelin receptor-B (EDNRB) leads to severe hypogangli

116 fected in HSCR encodes the G protein-coupled endothelin receptor-B (EDNRB).

117 The G-protein coupled receptor, endothelin receptor-B, and its ligand, endothelin-3, are

118 es that depend on both the G-protein-coupled endothelin receptor b1 (ednrb1) and the kit-related fms

119 We show that rose corresponds to endothelin receptor b1 (ednrb1), an orthologue of amniot

120 We show that Endothelin receptor B2 (EDNRB2) and EphB2 are both deter

121 were undertaken to test the hypothesis that endothelin receptor blockade can reduce neointimal thick

122 earm vasodilatation, the systemic effects of endothelin receptor blockade in healthy humans are unkno

123 nels via a mechanism possibly independent of endothelin receptor blockade.

124 Endothelin-receptor blockade provides haemodynamic benef

125 This effect was inhibited by a nonselective endothelin receptor blocker and by a selective ET(B) rec

126 However, the endothelin receptor blocker bosentan prevented the reduc

127 Bosentan, a dual endothelin receptor blocker, has been used clinically to

128 Pretreatment with PD 145065 (a nonselective endothelin receptor blocker; 50 micrograms.kg-1.min-1) c

129 ts may constitute the mechanism of action of endothelin receptor blockers in DN.

130 cted patients with essential hypertension to endothelin receptor blockers.

131 uid and that inhibition of B- but not A-type endothelin receptors blunts the decreased HCO3 secretion

132 animals given a specific inhibitor of A-type endothelin receptors (BQ-123) did not (-2.0+/-0.2 pmol m

133 Availability of cDNA clones for endothelin receptors can facilitate our understanding of

134 nearly abolished by PKC-IP, indicating that endothelin receptors could still activate PKC in 10 mm d

135 ctional role for PKCepsilon as a mediator of endothelin receptor-dependent increases in cytosolic cal

136 ing that PKCepsilon plays a critical role in endothelin receptor-dependent increases in intracellular

137 T assay used here provides new insights into endothelin-receptor dimer function, and represents a uni

138 iogenic mediators, including endothelins and endothelin receptor (EDNR) A.

139 helin family member Edn3, acting through the endothelin receptor EdnrA, directs extension of axons of

140 he purpose of this study was to determine if endothelin receptor (ET-R) blockade during HPP would imp

141 onstrate that mice deficient for one type of endothelin receptor, ETA, mimic the human conditions col

142 he endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for thera

143 The endothelin receptors, ETA and ETB, have differential tis

144 The predominant endothelin receptor expressed by normal prostate epithel

145 our knowledge of endothelin-1 synthesis and endothelin receptor expression and function in normal an

146 evated ET-1 and the cell-specific pattern of endothelin receptor expression suggest that the endothel

147 tions, infarct volume, oxidative stress, and endothelin receptors following permanent middle cerebral

148 Blockade of endothelin receptors for 28 days with only a mixed ET(A)

149 bosentan (10 mg/kg) to inhibit A- and B-type endothelin receptors had higher HCO3 secretion than base

150 Most recently the Endothelin receptor has been implicated in multiple tumo

151 Experiments were designed to characterize endothelin receptors in bronchi and parenchyma of transp

152 ednra and ednrb, the genes encoding the two Endothelin receptors in mice, were born at predicted Men

153 ortant vasoregulatory molecule, the roles of endothelin receptors in specific cell types are not yet

154 The Value of Endothelin Receptor Inhibition With Tezosentan in Acute

155 development and suggest that modification of endothelin receptor-ligand specificity was a key step in

156 fore, the thrombin, LPA, thromboxane A2, and endothelin receptors may be able to couple to Galpha12/1

157 bination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control

158 Endothelin receptors, particularly the ET(A) receptor, h

159 These data further implicate dysregulated endothelin-receptor pathways in fibroblasts in the patho

160 In mice, podocyte-specific knockout of the endothelin receptor prevented the diabetes-induced incre

161 ated by activation of the melanocortin 1 and endothelin receptors, respectively.

162 cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, the

163 These findings indicate that the pathway for endothelin receptor stimulation of MAPK involves PKCepsi

164 s study, we have examined the effects of the endothelin receptor subtype A antagonist, Ro 61-1790, on

165 that retained full receptor affinity at both endothelin receptor subtypes along with enhanced proteol

166 ve for the ET(A) (BQ-485) and ET(B) (BQ-788) endothelin receptor subtypes.

167 , the coupling of seven-transmembrane domain endothelin receptors to Gz proteins provided a pathway t

168 The endothelin receptor type A (EDNRA) signaling pathway is

169 and growth of the mammalian heart by binding endothelin receptor type A (ET(A)) and endothelin recept

170 dothelin (ET) 1 and angiotensin (Ang) II via endothelin receptor type A (ETAR) and Ang receptor type-

171 on chromosome 4q31.23, immediately 5' of the endothelin receptor type A with P = 2.2 x 10(-8) [odds r

172 ing the RET receptor tyrosine kinase and the endothelin receptor type B (EDNRB) are central to the ge

173 ncoding the RET receptor tyrosine kinase and endothelin receptor type B (EDNRB) are involved in HSCR

174 Mutations in the gene encoding the endothelin receptor type B (EDNRB) produce congenital ag

175 One of the genes associated with HSCR is endothelin receptor type B (Ednrb).

176 nding endothelin receptor type A (ET(A)) and endothelin receptor type B (ET(B)) G-protein-coupled rec

177 These cells highly expressed endothelin receptor type B (ETB(R)) and Jagged1, a Notch

178 otein endothelin 3 (EDN3), its receptor (the endothelin receptor type B [EDNRB]), and the transcripti

179 , small molecule agonists and antagonists of endothelin receptor type B administered in slice culture

180 as a regenerative pathway and suggests that endothelin receptor type B agonists represent a promisin

181 Antagonists of endothelin receptor type B also inhibited remyelination

182 phatase 2 was validated, and upregulation of endothelin receptor type B and interleukin-18 was valida

183 rk therefore identifies endothelin 2 and the endothelin receptor type B as a regenerative pathway and

184 n post-mortem tissue revealed high levels of endothelin receptor type B in oligodendrocyte lineage ce

185 genome sequencing, we discovered that EDNRB (Endothelin receptor type B) is a candidate gene involved

186 and significantly increase the expression of endothelin receptors upon maturation.

187 Endothelin receptors were still functional in 10 mm d-gl

188 Indeed, blockade of ETA endothelin receptors with BQ-610 (1 microM), similar to

189 protein ligands (in rodents), c-Kit, and the endothelin receptors with their ligands.